| Welcome to Inland Cardiology Research! |
| |
| The Research Department at Inland Cardiology has been involved with medical research for over 20 years. We take special pride in contributing to the advancement of medicine through our participation in clinical trials. We currently have two Principal Investigators, four sub-investigators and three clinical research coordinators. |
FAQ
What is a clinical trial?
Clinical trials are research studies that follow pre-defined protocols, to determine whether a specific treatment is better than what is currently available. Participants in clinical trial can play a more active role in their health care, and often gain access to new treatments that are not widely available.
Who can participate in a clinical trial?
Every clinical trial is different and has several inclusion and exclusion criteria for participation. Generally, if you are above the age of 18, can read and understand the informed consent form, and can attend all scheduled research visits; you may be eligible to participate.
What are the benefits to participating in clinical trials?
Participants in clinical trials are given the same top notch medical care with Inland Cardiology but also get additional checkups with our research staff. When you participate in a clinical trial you are becoming an important contributor to healthcare of tomorrow. Some studies do provide compensation for your time and effort of participation.
Participation and Obligations
If you are screened for a study and approved to be an active participant there are things you should consider before becoming involved. Participation in clinical trials work on a volunteer basis and you are agreeing to provide your attention and time to the study. Many studies require you to keep logs, medications, and journals. If you choose to participate, you would be responsible for keeping research staff informed of any changes to your healthcare, medications, procedures, etc. Most studies require a long term commitment, so as many as 5 years of follow up; be sure you understand the anticipated duration of the study prior to participating.
Your participation in a research study will not affect your ability to receive treatment for other medical conditions.
Why participate?
You have the chance to take part in investigational treatment that is not readily available. By participating you are also helping in the development of medical treatments that may help others.
|
 |
Top
LOCATION
Inland Cardiology Research
122 W. 7th Avenue Suite 450
Spokane, WA 99204
1-800-422-7060
(509) 462-3189
research@inlandcardiology.com
We are located on Spokane’s South Hill in the Heart and Vascular Institute building that is connected to Sacred Heart Medical Center. Our office features the latest in cardiac technology along with a caring and supportive staff. We maintain the strictest confidentiality with our patients through Electronic Medical Records (EMR’s) and thorough employee screening.
We strive for excellency in research through our committed and well educated physicians’ and staff. Please contact our friendly staff today to find out more.
STAFF
Primary Investigators
Joel R. Galloway, MD, FACC, FACP
Dr. Galloway joined Inland Cardiology in 1994 and since has been actively involved in research. His interests include interventional cardiology and peripheral vascular intervention. He is Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. Dr. Galloway is currently running three clinical trials at Inland Cardiology.
Donald B. Canaday, MD, FACC, FSCAI
Dr. Canaday joined Inland Cardiology in 1984 and also has a passion for research. His special interests include pacemakers, angioplasty, coronary stenting and rotablation. He is Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. Dr. Canaday is currently running four clinical trials.
Sub-Investigators
|
Clinical Research Coordinators
Tracy Love, RN, BSN
Mike Dauer, MS
Regulatory and Finance Specialist
Krista Alvarado-Phillips, BA
|
CONTACT US
Inland Cardiology Research
122 W. 7th Avenue Suite 450
Spokane, WA 99204
1-800-422-7060
(509) 462-3189
research@inlandcardiology.com
STUDIES
Study History – Phase III Pharmaceutical |
| |
|
| SOLID- TIMI 52 (SB-480848) |
Start Date Jan 2010-Ongoing |
A Clinical Outcomes Study of Darapladib versus Placebo in subjects following Acute Coronary Syndrome to compare the incidence of Major Adverse Cardiovascular Events (MACE).
Sponsor: GlaxoSmithKline |
| |
|
| TRA 2°P-TIMI 50 (P04737) |
Start Date: Aug 2009-Ongoing |
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease.
Sponsor: Schering-Plough Research Institute |
| |
|
| ENGAGE-TIMI 48 (DU-176b-C-U301) |
Start Date: July 2009-Ongoing |
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National study for Evaluation of Efficacy and Safety of DU-176b versus Warfarin in Subjects with Atrial Fibrillation.
Sponsor: Daiichi Sankyo Pharma Development |
| |
|
| APPRAISE-2 (CV185068) |
Start Date: May 2009-Ongoing |
A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome.
Sponsor: Bristol-Myers Squibb Research & Development |
| |
|
| STABILITY (LPL100601) |
Start Date: Jan. 2009-Sept. 2009 |
A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of major Adverse Cardiovascular Events (MACE).
Sponsor: GlaxoSmithKline |
| |
|
| TRA-CER (P04736) |
Start Date: July 2008-Ongoing |
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome.
Sponsor: Schering-Plough Research Institute
|
| |
Study History - Randomized Device Trials |
| |
|
| The DAPT Study (G080186) |
Start Date: April/May 2010 |
| HCRI |
|
| A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions. |
| |
|
PROVIDE (CRD 448) |
Start Date: Feb. 2009-March 2010 |
Programming Implantable Cardioverter Defibrillators in Patients with Primary Prevention Indication to Prolong Time to First Shock.
Sponsor: St. Jude Medical
|
| |
|
| Spirit-PRIME (06-373) |
Start Date: Dec. 2009-Ongoing |
A Clinical Evaluation of the XIENCE PRIME ™ and XIENCE PRIME ™ LL Everolimus Eluting Coronary Stent System.
Sponsor: Abbott Cardiovascular Systems, Inc |
| |
| Study History – Device Registries |
| |
|
| RATE (CRD 374) |
Start Date: Mar. 2008-March 2010 |
Registry of AT/AF Episodes in the CRM Device Population
Sponsor: St. Jude Medical |
| |
|
| OPTIMUM (CD0196) |
Start Date: June 2008-March 2010 |
OptimTM Lead Insulation Material Registry
Sponsor: St. Jude Medical |
| |
|
| GAME (CV185068) |
Start Date: June 2008-July 2009 |
Genetic Arrhythmia Markers for Early Detection.
Sponsor: Medtronic, Inc.
|
| |
|
| CRT on DFT (CD0212) |
Start Date: Apr. 2008-Sept. 2009 |
Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates.
Sponsor: St. Jude Medical
|
|
| |
|
| |
|
